ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Emexa Therapeutics Inc

Emexa Therapeutics Inc (ERNA)

2.53
0.14
(5.86%)
2.46
-0.07
(-2.77%)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
2.46
Bid
2.28
Ask
2.53
Volume
97,980
2.3207 Day's Range 2.59
2.08 52 Week Range 39.375
Market Cap
Previous Close
2.39
Open
2.38
Last Trade
1
@
2.4
Last Trade Time
Financial Volume
$ 240,085
VWAP
2.4503
Average Volume (3m)
378,921
Shares Outstanding
7,361,201
Dividend Yield
-
PE Ratio
-0.41
Earnings Per Share (EPS)
-6.05
Revenue
582k
Net Profit
-44.56M

About Emexa Therapeutics Inc

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease. Ernexa's core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa's a... Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease. Ernexa's core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa's allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting. Show more

Sector
Pharmaceutical Preparations
Industry
Television Broadcast Station
Headquarters
Wilmington, Delaware, USA
Founded
2022
Emexa Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ERNA. The last closing price for Emexa Therapeutics was $2.39. Over the last year, Emexa Therapeutics shares have traded in a share price range of $ 2.08 to $ 39.375.

Emexa Therapeutics currently has 7,361,201 shares outstanding. The market capitalization of Emexa Therapeutics is $17.59 million. Emexa Therapeutics has a price to earnings ratio (PE ratio) of -0.41.

ERNA Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.2835-10.33351558232.74352.74932.089273512.34961695CS
4-0.993-28.75760208513.4533.7499852.087297632.80940088CS
12-1.515-38.11320754723.9754.01852.083789212.90592534CS
26-1.6245-39.77230995234.084514.42.0854457106.69503878CS
52-26.94-91.632653061229.439.3752.0828399056.65001775CS
156-60.54-96.095238095263107.252.0810827547.68188139CS
260-60.54-96.095238095263107.252.0810827547.68188139CS

ERNA - Frequently Asked Questions (FAQ)

What is the current Emexa Therapeutics share price?
The current share price of Emexa Therapeutics is $ 2.46
How many Emexa Therapeutics shares are in issue?
Emexa Therapeutics has 7,361,201 shares in issue
What is the market cap of Emexa Therapeutics?
The market capitalisation of Emexa Therapeutics is USD 17.59M
What is the 1 year trading range for Emexa Therapeutics share price?
Emexa Therapeutics has traded in the range of $ 2.08 to $ 39.375 during the past year
What is the PE ratio of Emexa Therapeutics?
The price to earnings ratio of Emexa Therapeutics is -0.41
What is the cash to sales ratio of Emexa Therapeutics?
The cash to sales ratio of Emexa Therapeutics is 31.61
What is the reporting currency for Emexa Therapeutics?
Emexa Therapeutics reports financial results in USD
What is the latest annual turnover for Emexa Therapeutics?
The latest annual turnover of Emexa Therapeutics is USD 582k
What is the latest annual profit for Emexa Therapeutics?
The latest annual profit of Emexa Therapeutics is USD -44.56M
What is the registered address of Emexa Therapeutics?
The registered address for Emexa Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
Which industry sector does Emexa Therapeutics operate in?
Emexa Therapeutics operates in the TELEVISION BROADCAST STATION sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CEROCERo Therapeutics Holdings Inc
$ 19.92
(190.04%)
57.35M
ACXPAcurx Pharmaceuticals Inc
$ 0.8149
(165.35%)
337.45M
EYENEyenovia Inc
$ 6.96
(134.34%)
29.94M
RBNERobin Energy Ltd
$ 10.60
(92.03%)
45.44M
RELIReliance Global Group Inc
$ 2.20
(86.44%)
19.29M
SDSTStardust Power Inc
$ 0.186
(-52.10%)
39.42M
SHOTWSafety Shot Inc
$ 0.0161
(-45.97%)
12.35k
RUNSunrun Inc
$ 5.78
(-40.04%)
120.05M
SEDGSolarEdge Technologies Inc
$ 15.94
(-33.53%)
33.14M
GOVXGeoVax Labs Inc
$ 0.8924
(-32.39%)
2.64M
PCSAProcessa Pharmaceuticals Inc
$ 0.2632
(16.93%)
575.5M
GNLNGreenlane Holdings Inc
$ 0.0104
(-16.13%)
392.94M
HCTIHealthcare Triangle Inc
$ 0.022
(-16.67%)
356.57M
ACXPAcurx Pharmaceuticals Inc
$ 0.8149
(165.35%)
337.45M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 11.9373
(-7.75%)
143.55M

ERNA Discussion

View Posts
glenn1919 glenn1919 1 month ago
ERNA................................https://stockcharts.com/h-sc/ui?s=ERNA&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 3 months ago

Ernexa’s technology transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), which are a specialized type of stem cell that has a unique ability to migrate toward tumors or inflammation. Ernexa’s allogeneic synthetic iMSCs allow for enhanced predictability at scale, helping to avoid the challenges of immune rejection and donor shortages.Ernexa has two cell therapy products in development, which are undergoing preclinical trials. Its lead cell therapy product, ERNA-101, is engineered to enhance and regulate the immune system’s response, enabling it to identify and eliminate cancer cells. ERNA-102 is designed to combat inflammation and treat autoimmune disease.ERNA-101 is being developed for the treatment of ovarian cancer as its first indication. There is a significant unmet need in ovarian cancer, which currently lacks highly effective, widely applicable targeted therapies. Many patients develop resistance to the standard treatment in ovarian cancer – platinum-based chemotherapy. Other treatments have been developed but with little success.ERNA-101 and ERNA-102 have the potential to bring significant hope in the treatments of ovarian cancer and autoimmune disease, respectively.Ernexa’s ticker symbol will remain as ERNA.
👍️0
glenn1919 glenn1919 5 months ago
ERNA....................https://stockcharts.com/h-sc/ui?s=ERNA&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 5 months ago
Getting rid of .33/34 half out .70 almost all out .93 
👍️ 1
glenn1919 glenn1919 5 months ago
erna...............................https://stockcharts.com/h-sc/ui?s=erna&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 5 months ago
ERNA..............................https://stockcharts.com/h-sc/ui?s=ERNA&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 6 months ago
.33/34 at .27 average this round 
👍️0
glenn1919 glenn1919 6 months ago
erna.......................https://stockcharts.com/h-sc/ui?s=erna&p=W&b=5&g=0&id=p86431144783
👍️0
Fairgrounds Fairgrounds 6 months ago
.3256
👍️0
tw0122 tw0122 6 months ago
.30 +
20%
👍️0
tw0122 tw0122 6 months ago
.32 the .20s will pay off
👍️0
tw0122 tw0122 6 months ago
$26-.27s looking better at .28
👍️0
tw0122 tw0122 6 months ago
Back in at .28 and they halt it
👍️0
tw0122 tw0122 6 months ago
The power of loading heavy at .28 beat down pays off
👍️0
tw0122 tw0122 6 months ago
Add .28s how low can she go longer term play perhaps 
👍️0
tw0122 tw0122 6 months ago
Back in at .30-.31 beat down price 
👍️0
glenn1919 glenn1919 6 months ago
ERNA........................................https://stockcharts.com/h-sc/ui?s=ERNA&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 6 months ago
70% profit out in .70s  paid off to load .40s
👍️0
tw0122 tw0122 7 months ago
Add.40-.42
👍 1 🚀 1
tw0122 tw0122 7 months ago
Back in .45 still have share buyback in place 
👍 1 💯 1
tw0122 tw0122 7 months ago
.63 once it floats through weak resistance at .69-.71 off to dollar land $1
👍 1 🚀 1
tw0122 tw0122 7 months ago
.60 ..Even better off to $1 where it was last week 
👍 1 🚀 1
tw0122 tw0122 7 months ago
.55 now looking better
👍 1 🚀 1
tw0122 tw0122 7 months ago
In on .4999s hopefully bottom in at .51
👍️0
glenn1919 glenn1919 7 months ago
ERNA.......................https://stockcharts.com/h-sc/ui?s=ERNA&p=W&b=5&g=0&id=p86431144783

.

....................thx.....lost in the shuffle again..................
👍️0
tw0122 tw0122 7 months ago
1 million share buyback on this 2 million floater going to skyrocket..😵🥴🚀🚀🚀🚀🚀🚀🚀🚀

Eterna Therapeutics Announces Up to $1 Million Stock Repurchase ProgramNovember 25 2024 - 8:30AM

👍️0
tw0122 tw0122 7 months ago
Right back to $1s with announcement...91- 1.28 next profit zone.. The effective date of the reverse stock split has not yet been determined and will be announced by the Company at least two business days prior to its implementation.
👍 1 🚀 1
tw0122 tw0122 7 months ago
Board is retarded you can't comment on DDC without getting permission to start board 
👍️0
Invest-in-America Invest-in-America 7 months ago
ERNA: Yep, been scrutinizing that puppy tonight. (And comment about DDC???)
👍 1 🔥 1
tw0122 tw0122 7 months ago
Cooling down $1.10 + 31%
👍️0
Invest-in-America Invest-in-America 7 months ago
ERNA: Up circa 46% in the Post-Market right now --- likely continued reaction to regaining NASDAQ compliance, YESTERDAY.
👍️0
glenn1919 glenn1919 9 months ago
ERNA.........................https://stockcharts.com/h-sc/ui?s=ERNA&p=W&b=5&g=0&id=p86431144783
👍️0

Your Recent History

Delayed Upgrade Clock